Bispecific TNFR2-4-1BB Antibody for Selective T Cell Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies targeting TNFR2 and 4-1BB for immune regulation in cancer and autoimmune diseases are limited in their ability to simultaneously activate effector T cells and inhibit regulatory T cells, leading to suboptimal immune response.

Innovation Solution

Development of a bispecific antibody that binds to both TNFR2 and 4-1BB, utilizing agonistic anti-TNFR2 monoclonal antibodies to stimulate CD8+ T cells and activate 4-1BB signaling pathways, enhancing cytotoxic T cell and NK cell activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If separate monoclonal antibodies targeting TNFR2 and 4-1BB are used, then each pathway can be activated independently, but the ability to simultaneously regulate effector T cells and regulatory T cells is limited

Engineering Contradiction:

Improveability to simultaneously activate effector T cells and inhibit regulatory T cellsVSAvoidcomplexity of using multiple separate antibodies

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent combines two separate monoclonal antibodies into a single bispecific antibody molecule that simultaneously targets both TNFR2 and 4-1BB. This merging allows the single antibody to activate effector T cells through TNFR2 while simultaneously providing co-stimulatory signals through 4-1BB, thereby enhancing anti-tumor immunity without requiring separate administration of multiple antibodies

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The bispecific antibody serves multiple functions within a single molecule: it acts as a TNFR2 agonist to activate effector T cells, provides 4-1BB co-stimulatory signaling to enhance T cell proliferation and survival, and selectively targets tumor-infiltrating lymphocytes. This multi-functionality resolves the limitation of separate antibodies by integrating multiple therapeutic mechanisms into one agent

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If TNFR2 agonist monoclonal antibodies are used to stimulate CD8+ T cells, then anti-tumor activity is enhanced, but the selective inhibition of regulatory T cells is insufficient

Engineering Contradiction:

Improveselectivity in activating effector T cells while inhibiting regulatory T cellsVSAvoidinsufficient immune regulation leading to suboptimal anti-tumor response

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The bispecific antibody exploits the differential expression patterns of TNFR2 and 4-1BB on different T cell subsets to achieve selective activation. Effector T cells express both antigens at levels that permit strong dual signaling, while regulatory T cells have expression patterns that result in different signaling outcomes. This local quality difference in antigen expression enables selective immune regulation

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The bispecific antibody acts as an intermediary that translates the differential surface expression of TNFR2 and 4-1BB into selective biological responses. By simultaneously engaging both antigens, the antibody creates a signaling pattern that preferentially activates effector T cells while having a different effect on regulatory T cells, thereby achieving selective immune modulation

Inventive Principle:

Principle #24Intermediary (Mediator)

3Productivity

If 4-1BBL is used to provide co-stimulatory signals for T cell activation, then T cell proliferation is enhanced, but the combined effect with TNFR2 activation is not achieved

Engineering Contradiction:

ImproveT cell proliferation and activationVSAvoidability to coordinate TNFR2 and 4-1BB signaling pathways

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The patent merges the functions of separate TNFR2 agonist antibodies and 4-1BBL co-stimulatory molecules into a single bispecific antibody. This allows simultaneous engagement of both TNFR2 and 4-1BB on the same T cell, coordinating the signaling from both pathways to produce synergistic effects on T cell activation, proliferation, and anti-tumor function

Inventive Principle:

Principle #5Merging (Combining)

Data Source

PatentUS20260049151A1Bispecific antibody binding to TNFR2 and 4-1bb

Publication Date: 2026.02.19 SHENGHE CHINA BIOPHARMACEUTICAL CO LTD

AI summary

A bispecific antibody, including: a first antibody or antigen-binding fragment thereof that specifically binds to a first antigen; a second antibody or antigen-binding fragment thereof that specifically binds to a second antigen; where the first antigen is TNFR2, and the second antigen is 4-1BB; or, the first antigen is 4-1BB, and the second antigen is TNFR2. The bispecific antibody is a T cell regulator of the tumor microenvironment, which can stimulate the proliferation of CD8+T cells, activate CD8+T cells, and release anti-tumor factors, such as IFNγ and IL2 by using a TNFR2 agonistic antibody, or can block TNF-TNFR2 and inhibit the proliferation of Treg by using a TNFR2 antagonistic antibody. The bispecific antibody can simultaneously target 4-1BB, activate the 4-1BB signaling pathway of T cells and NK cells, enhance the killing power of cytotoxic T cells and NK cells, and produce anti-tumor activity.